Physician Photo

Fawn A. Leigh, MD

Director, Pediatric Neuromuscular Service

Department of Neurology


  • Cancer Center
  • Neuro-Oncology (Brain)
  • Neurofibromatosis
  • MassGeneral Hospital for Children
  • Neuromuscular Service
  • Neurology
Clinical Interests
Pediatric Neuromuscular disorders
Neurogenetic disorders
Clinical research
Drug Development
Boston: Massachusetts General Hospital
Medical Education
MD, University of Chicago Pritzker School of Medicine
Residency, University of Chicago/Comer Children's Hospital
Board Certifications
Neurology with Special Qualifications in Child Neurology, American Board of Psychiatry and Neurology
Patient Gateway
Yes, learn more
Patient Age Group
Adult and pediatric
Accepting New Patients
Accepting New Patients

BiographyDr. Leigh earned her medical degree at the University of Chicago Pritzker School of Medicine, where she also completed training in General Pediatrics, followed by Adult and Child Neurology.  Following completion of specialty training, she joined Duke University in the Departments of Pediatrics and Medicine. At Duke University Medical Center, she developed the Duke Neurofibromatosis Clinic and Biobank.  She directed the Duke Neurofibromatosis Clinic until her recruitment to Massachusetts General Hospital.  Dr. Leigh is also the Director of the Pediatric Neuromuscular Service, which provides mulitidisciplinary care for muscular dystrophies, congenital myopathies, juvenile myasthenia gravis and motor neuron disorder including spinal muscular atrophy and charcot marie tooth. Her expertise in providing multidisciplinary care to pediatric, as well as, adult patients strengthens our program?s family-centered treatment model to provide specialized and continued care for both children and adults

ResearchIn Neurofibromatosis, type 1 (NF1), clinical variability is common.  Prior studies of families affected by NF1 have implicated trait-specific modifier genes as important determinants of the clinical variability in NF1.  The focus of Dr. Leigh's research is directed at searching for modifiers of tumor development, whose identification may provide us with potential therapeutic targets, as well as clues to better understanding of the underlying mechanisms in tumor development. Dr. Leigh expanded this research into understanding Duchenne Muscular Dystrophy(DMD), a neurogenetic condition affecting muscle and multiple organ systems with clinical variability.  Trait specific modifiers related to severity of disease can provide greater insight towards targeted therapies in this complex, multi-system condition.  Current research efforts in DMD include clinical trials and drug development.

Neurofibromatosis Clinic
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-724-8770
Fax: 617-724-8769

Pediatric Neuromuscular Clinic
165 Cambridge St
Boston, MA 02114

Phone: 617-643-4645
Fax: 617-724-7660